Prognostic factors for patients treated with abiraterone

AIM: To evaluate prostate-specific antigen response (PSAr) defined as a ≥50% decrease in PSA concentration from the pretreatment value, as a prognostic factor in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA). METHODS: Retrospective evalua...

Descripción completa

Detalles Bibliográficos
Autores principales: Alvim, Cecília M, Mansinho, André, Paiva, Rita S, Brás, Raquel, Semedo, Patrícia M, Lobo-Martins, Soraia, da Ponte, Carolina B, Macedo, Daniela, Ribeiro, Leonor, dos Reis, José P, Fernandes, Isabel, Costa, Luís
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Science Ltd 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997918/
https://www.ncbi.nlm.nih.gov/pubmed/32025327
http://dx.doi.org/10.2144/fsoa-2019-0079
Descripción
Sumario:AIM: To evaluate prostate-specific antigen response (PSAr) defined as a ≥50% decrease in PSA concentration from the pretreatment value, as a prognostic factor in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA). METHODS: Retrospective evaluation of patients with mCRPC treated with AA. RESULTS: 124 patients were identified. Median overall survival and progression-free survival for patients achieving PSAr versus patients without PSAr were 29.3 versus 9.7 months and 17.0 versus 5.2 months, respectively. Multivariate analysis confirmed that PSAr correlated with better overall survival (hazard ratio: 0.19; 95% CI: 0.10−0.38; p < 0.001) and progression-free survival (hazard ratio: 0.24; 95% CI: 0.14−0.41; p < 0.001). CONCLUSION: PSAr can be utilized as prognostic and predictive factors in mCRPC patients treated with AA.

Ejemplares similares